We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-6.02%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.53B
AUM Growth
-$325M
Cap. Flow
-$296M
Cap. Flow %
-19.34%
Top 10 Hldgs %
65.86%
Holding
300
New
43
Increased
68
Reduced
83
Closed
84

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$95.6M
2
TSRO
TESARO, Inc.
TSRO
+$7.45M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$5.41M
4
MBOT icon
Microbot Medical
MBOT
+$4.73M
5
UTHR icon
United Therapeutics
UTHR
+$4.46M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$6.09M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$5.39M
3
MTFB
Motif Bio plc ADRs
MTFB
+$4.6M
4
OTIC
Otonomy, Inc.
OTIC
+$3.19M
5
PALI icon
Palisade Bio
PALI
+$2.63M

Sector Composition

Rank Sector Weight
1 Healthcare 13%
2 Materials 0.27%
3 Financials 0.11%
4 Consumer Staples 0.03%
5 Consumer Discretionary 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APDNW
101
DELISTED
Applied DNA Sciences Inc Warrant
APDNW
$980K 0.06%
2,389,305
-41,784
-2% -$14.5K
XENE icon
102
Xenon Pharmaceuticals
XENE
$6.28B
$979K 0.06%
310,808
+14,330
+5% +$56K
NTLA icon
103
Intellia Therapeutics
NTLA
$1.52B
$960K 0.06%
60,000
-80,000
-57% -$1.12M
ANTH
104
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$960K 0.06%
592,672
+372,960
+170% +$836K
OTIC
105
DELISTED
Otonomy, Inc.
OTIC
$946K 0.06%
50,205
-228,635
-82% -$3.19M
ROKA
106
DELISTED
Sorrento Tech, Inc. Common Stock
ROKA
$945K 0.06%
358,198
-30,938
-8% -$98.7K
CDTX
107
DELISTED
Cidara Therapeutics
CDTX
$938K 0.06%
6,250
-2,630
-30% -$364K
MRTX
108
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$921K 0.06%
255,100
+5,365
+2% +$20.6K
ABUS icon
109
Arbutus Biopharma
ABUS
$871M
$895K 0.06%
248,600
-399,600
-62% -$1.37M
MNKD icon
110
PUT
MannKind Corp
MNKD
$1.21B
$864K 0.06%
6,126
-16,888
-73% -$21.7K
TPST icon
111
Tempest Therapeutics
TPST
$13.9M
$795K 0.05%
174
+29
+20% +$123K
SPHS
112
DELISTED
Sophiris Bio, Inc.
SPHS
$787K 0.05%
357,792
+14,370
+4% +$35.2K
DRRX
113
CALL
DELISTED
DURECT Corp
DRRX
$758K 0.05%
486
-136
-22% -$1.55K
LXRX icon
114
PUT
Lexicon Pharmaceuticals
LXRX
$1.04B
$752K 0.05%
457
+82
+22% +$1.27K
CTSO icon
115
Cytosorbents Corp
CTSO
$23.3M
$740K 0.05%
172,100
-47,900
-22% -$210K
CBMXW
116
DELISTED
CombiMatrix Corporation Warrant
CBMXW
$731K 0.05%
545,309
-74,441
-12% -$98.4K
OPGN
117
DELISTED
OpGen, Inc
OPGN
$724K 0.05%
11
– –
NTLA icon
118
CALL
Intellia Therapeutics
NTLA
$1.52B
$723K 0.05%
452
+200
+79% +$2.79K
IRD
119
Opus Genetics
IRD
$282M
$706K 0.05%
+5,145
New +$1M
FOCL
120
PUT
EDAP TMS S.A.
FOCL
$227M
$688K 0.05%
2,086
+143
+7% +$407
DRRX
121
DELISTED
DURECT Corp
DRRX
$663K 0.04%
42,500
-123,461
-74% -$1.41M
CLVS
122
DELISTED
Clovis Oncology, Inc.
CLVS
$661K 0.04%
+7,065
New +$432K
DMK
123
PUT
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
$651K 0.04%
+18
New +$5.39K
ATEC icon
124
Alphatec Holdings
ATEC
$1.43B
$629K 0.04%
+334,622
New +$676K
MDCO
125
CALL
DELISTED
Medicines Co
MDCO
$612K 0.04%
161
-159
-50% -$7.08K
3 4
5
6 7

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2017 Portfolio in Review

As of Q2 2017, Sabby Management held 300 positions worth $1.53B, down 18% from $1.85B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Sabby Management withdrew a net $296M in Q2 2017, closing 84 positions and reducing 83 holdings. Its most notable exit was Amgen, an estimated $6.09M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 13% of assets, up from 6.3% a quarter earlier, followed by Materials and Financials.

Against the trend, Sabby Management opened a new position in TESARO, Inc. worth $7.19M.

  • Sabby Management's largest Q2 2017 buy was TESARO, Inc.: 51,426 shares worth $7.19M.
  • Sabby Management added most to Bristol-Myers Squibb in Q2 2017, an estimated $95.6M increase.
  • Sabby Management's biggest Q2 2017 reduction was Otonomy, Inc., cutting an estimated $3.19M.
  • Sabby Management fully exited Amgen in Q2 2017, selling an estimated $6.09M.
  • Sabby Management's ten largest holdings make up 66% of its $1.53B portfolio in Q2 2017.
  • Sabby Management opened 43 new positions and closed 84 in Q2 2017.
  • Sabby Management's portfolio value fell 18% quarter-over-quarter to $1.53B.

Based on Sabby Management's 13F filing for Q2 2017, filed 14 Aug 2017.